EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #72192_C
前列腺素通路激活剂；激活前列腺素受体 EP1、EP2、EP3 和 EP4
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
总览
前列腺素E₂ (PGE₂) 是生物活性最高、研究最深入的前列腺素。它与EP1、EP2、EP3和EP4受体具有极高的亲和力（Ki分别为9.1、4.9、0.33和0.79 nM）。（Abramovitz et al., Bos et al.）
维持和自我更新
·是小鼠和斑马鱼造血干细胞 (HSC) 发育所必需的（North et al.）。
可能通过促进归巢、存活和/或自我更新来改善小鼠造血干细胞的植入（Hoggatt et al. 2009, Hoggatt et al. 2013, North et al.）。
分化
·促进小鼠、恒河猴和人胚胎干细胞向造血祖细胞分化（Gori et al., North et al., Woods et al.）。
·促进髓系来源的抑制细胞从造血祖细胞分化（Sinha et al.）。
·促进 Th17 细胞从 naïve T 细胞分化（Boniface et al.）。
别名
Dinoprostone；PGE2
细胞类型
造血干/祖细胞，髓系细胞，多能干细胞，T 细胞
种属
人，小鼠，非人灵长类，其它细胞系，大鼠
应用
分化，培养
研究领域
干细胞生物学
CAS 编号
363-24-6
化学式
C₂₀H₃₂O₅
分子量
352.5 克/摩尔
纯度
≥98%
通路
前列腺素衍生物
靶点
前列腺素受体
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (3)
文献 (10)
Gut-Liver Physiomimetics Reveal Paradoxical Modulation of IBD-Related Inflammation by Short-Chain Fatty Acids. Cell systems 2020 mar
Abstract
Although the association between the microbiome and IBD and liver diseases is known, the cause and effect remain elusive. By connecting human microphysiological systems of the gut, liver, and circulating Treg and Th17 cells, we created a multi-organ model of ulcerative colitis (UC) ex vivo. The approach shows microbiome-derived short-chain fatty acids (SCFAs) to either improve or worsen UC severity, depending on the involvement of effector CD4 T cells. Using multiomics, we found SCFAs increased production of ketone bodies, glycolysis, and lipogenesis, while markedly reducing innate immune activation of the UC gut. However, during acute T cell-mediated inflammation, SCFAs exacerbated CD4+ T cell-effector function, partially through metabolic reprograming, leading to gut barrier disruption and hepatic injury. These paradoxical findings underscore the emerging utility of human physiomimetic technology in combination with systems immunology to study causality and the fundamental entanglement of immunity, metabolism, and tissue homeostasis.
Prostaglandin E2 enhances long-term repopulation but does not permanently alter inherent stem cell competitiveness. Blood 2013 OCT
Abstract
Hematopoietic stem cell (HSC) transplantation is a lifesaving therapy for malignant and nonmalignant hematologic diseases and metabolic disorders. Although successful, hematopoietic transplantation can be hindered by inadequate stem cell number or poor engrafting efficiency. To overcome these deficits, we and others have previously reported the HSC-enhancing ability of a short-term exposure of prostaglandin E2 (PGE2); this strategy has now progressed to phase 1 clinical trials in double cord blood transplantation. To further analyze the short- and long-term effects of HSC exposure to PGE2, we followed the repopulation kinetics of PGE2-treated hematopoietic grafts through 5 serial transplantations and compared inherent long-term competitiveness in a HSC head-to-head secondary transplantation model. Treatment with PGE2 did not result in a long-term increase in HSC competitiveness, lineage bias, or enhanced proliferative potential, demonstrating that pulse exposure to PGE2 results in transient increases in HSC homing and engraftment potential.
Efficient generation, purification, and expansion of CD34(+) hematopoietic progenitor cells from nonhuman primate-induced pluripotent stem cells. Blood 2012 SEP
Abstract
Induced pluripotent stem cell (iPSC) therapeutics are a promising treatment for genetic and infectious diseases. To assess engraftment, risk of neoplastic formation, and therapeutic benefit in an autologous setting, testing iPSC therapeutics in an appropriate model, such as the pigtail macaque (Macaca nemestrina; Mn), is crucial. Here, we developed a chemically defined, scalable, and reproducible specification protocol with bone morphogenetic protein 4, prostaglandin-E2 (PGE2), and StemRegenin 1 (SR1) for hematopoietic differentiation of Mn iPSCs. Sequential coculture with bone morphogenetic protein 4, PGE2, and SR1 led to robust Mn iPSC hematopoietic progenitor cell formation. The combination of PGE2 and SR1 increased CD34(+)CD38(-)Thy1(+)CD45RA(-)CD49f(+) cell yield by 6-fold. CD34(+)CD38(-)Thy1(+)CD45RA(-)CD49f(+) cells isolated on the basis of CD34 expression and cultured in SR1 expanded 3-fold and maintained this long-term repopulating HSC phenotype. Purified CD34(high) cells exhibited 4-fold greater hematopoietic colony-forming potential compared with unsorted hematopoietic progenitors and had bilineage differentiation potential. On the basis of these studies, we calculated the cell yields that must be achieved at each stage to meet a threshold CD34(+) cell dose that is required for engraftment in the pigtail macaque. Our protocol will support scale-up and testing of iPSC-derived CD34(high) cell therapies in a clinically relevant nonhuman primate model.
更多信息
| Molecular Weight | 352.5 g/mol |
|---|---|
| 种属 | Human, Mouse, Non-Human Primate, Other, Rat |
| Alternative Names | Dinoprostone, PGE2 |
| Cas Number | 363-24-6 |
| Chemical Formula | C₂₀H₃₂O₅ |
| 纯度 | ≥ 98% |
| Target | Prostaglandin Receptor |
| Pathway | Prostanoid |
相关产品
-
StemSpan™ SFEM II用于培养和扩增造血细胞的无血清培养基
-
16,16-二甲基前列腺素E2前列腺素通路激活剂；抑制 15-羟基 PGDH
质量保证:
产品仅供研究使用，不用于针对人或动物的诊断或治疗。
产品仅供研究使用，不用于针对人或动物的诊断或治疗。
